Indeed, the p300/CBP inhibitors A485 and CCS1477 robustly decreased H3K27Ac and c-Myc expression in both quizartinib-resistant FLT3-ITD AML cell lines with TKD mutations and primary AML patient samples. This evidence concerns the gene EP300 and acute myeloid leukemia.